210 related articles for article (PubMed ID: 19046740)
1. The endocannabinoid system as a target for obesity treatment.
Aronne LJ; Pagotto U; Foster GD; Davis SN
Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in obesity pharmacotherapy.
Mayer MA; Höcht C; Puyó A; Taira CA
Curr Clin Pharmacol; 2009 Jan; 4(1):53-61. PubMed ID: 19149502
[TBL] [Abstract][Full Text] [Related]
4. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy to reduce visceral fat.
Blackburn GL; Waltman BA
Clin Cornerstone; 2005; 7(2-3):52-60. PubMed ID: 16473261
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
Halford JC
Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
[TBL] [Abstract][Full Text] [Related]
7. [Endocannabinoid and endocannabinoid receptor antagonists].
Heinzl S
Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
[No Abstract] [Full Text] [Related]
8. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
9. Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
Padwal RS; Majumdar SR
Lancet; 2007 Jan; 369(9555):71-7. PubMed ID: 17208644
[TBL] [Abstract][Full Text] [Related]
10. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for obesity.
Neff LM; Aronne LJ
Curr Atheroscler Rep; 2007 Dec; 9(6):454-62. PubMed ID: 18377785
[TBL] [Abstract][Full Text] [Related]
12. Endocannabinoid control of food intake and energy balance.
Di Marzo V; Matias I
Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
14. The challenge of treating obesity: the endocannabinoid system as a potential target.
Isoldi KK; Aronne LJ
J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
[TBL] [Abstract][Full Text] [Related]
15. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Dibble CT; Gelfand EV; Cannon CP
Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
[TBL] [Abstract][Full Text] [Related]
16. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Rubio MA; Gargallo M; Isabel Millán A; Moreno B
Public Health Nutr; 2007 Oct; 10(10A):1200-5. PubMed ID: 17903331
[TBL] [Abstract][Full Text] [Related]
17. Role of the endocannabinoid system in energy balance regulation and obesity.
Cota D
Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
[TBL] [Abstract][Full Text] [Related]
18. [New therapeutic aspects for the control of risk factors in obesity].
Formiguera X; Sierra A
Med Clin (Barc); 2007 Apr; 128(13):508-14. PubMed ID: 17419915
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
Sander GE; Giles TD
Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895
[No Abstract] [Full Text] [Related]
20. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Lee M; Aronne LJ
Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]